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Background. Evaluating impact of tumor regression grade in prognosis of patients with locally advanced rectal cancer (LARC).
Materials and Methods. We identified from our colorectal cancer database 168 patients with LARC who received neoadjuvant
therapy followed by completemesorectum excision surgery between 2003 and 2011: 157 received 5-FU-based chemoradiation (CRT)
and 11 short course RT. We excluded 29 patients, the remaining 139 were reassessed for disease recurrence and survival; the slides
of surgical specimens were reviewed and classified according to Mandard tumor regression grades (TRG). We compared patients
with good response (Mandard TRG1 or TRG2) versus patients with bad response (Mandard TRG3, TRG4, or TRG5). Outcomes
evaluated were 5-year overall survival (OS), disease-free survival (DFS), local, distant and mixed recurrence. Results. Mean age
was 64.2 years, and median followup was 56 months. No statistically significant survival difference was found when comparing
patients with Mandard TRG1 versus Mandard TRG2 (𝑝 = .77). Mandard good responders (TRG1 + 2) have significantly better OS
and DFS than Mandard bad responders (TRG3 + 4 + 5) (OS 𝑝 = .013; DFS 𝑝 = .007). Conclusions. Mandard good responders
had a favorable prognosis. Tumor response (TRG) to neoadjuvant chemoradiation should be taken into account when defining the
optimal adjuvant chemotherapy regimen for patients with LARC.
1. Introduction
Colorectal cancer is the third most common cancer in
developed countries. It ranks second in Portugal, and it is
estimated that each yearmore than 7,000 new cases arise with
8 Portuguese patients with colorectal cancer dying per day,
on average [1, 2]. Surgery remains the primary therapeutic
tool in the treatment of rectal cancer, and with the advent
of mesorectum complete excision (TME) in cancers of the
middle and lower rectum, it was possible to reduce the
locoregional recurrence [3–6]. However, concerning locally
advanced rectal cancer (LARC), this approach has proved
insufficient to maintain levels of locoregional recurrence
between 4 and 6% [7, 8].
Neoadjuvant CRT allows a reduction of regional recur-
rences, and when there is a complete pathological response
(ypCR), an increase in survival is verified [9].
The rate of response is better in neoadjuvant CRT com-
paredwith long course RT and possibly absent in short course
RT with immediate surgery. In fact, the maximal response
of the radiation occurs only several weeks after its end [10].
For that reason, surgery has been delayed until 8–12 weeks
following neoadjuvant CRT [11–13].
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The use of neoadjuvant CRT can lead to tumor shrinkage,
increases the likelihood of performing a sphincter preserving
surgery, and in the surgical specimen increases circumfer-
ential and distal margins, with reduction of lymphatic and
vascular invasion [14–19].
However, the type and remission rate to neoadjuvant CRT
remain considerably variable. While some patients may not
respond, other patients experience downstaging, and 15–25%
have surgical specimens without any viable tumor cells, a
condition referred to as pathologic complete response (ypCR)
[20, 21].
Complete pathological response leads to excellent locore-
gional management as it provides an increase in survival for
stage I values, that is, 90% at 5 years [22–26]. Based on these
data, there are centers that in case of a ypCR advocate a policy
of “wait and see” reserving surgical resection only for cases of
“tumor escape.”The published results of these centers refer to
survival rates equal to or greater than those achieved in ypCR
patients with resection [27–30].
While there are substantial data regarding the relation-
ship between ypCR and improved oncologic outcomes, the
prognostic significance of “near complete” response to CRT
has not been extensively evaluated [31]. Therefore, the aim of
this study was to verify if the association of ypCR with near
complete response (good responders) maintains a similar
prognostic of ypCR alone in patients with LARC.
To quantify the response to neoadjuvant CRT, different
systems can be used which are particularly important in
situations where the pathological response is not complete.
Most of them have 5 grades, allowing the creation of groups
according to the response [20, 32, 33].
This study evaluates the degree of tumor regression
according to Mandard classification in patients with LARC
who underwent neoadjuvant CRT followed by surgical resec-
tion with TME.
2. Material and Methods
A single-institution database was queried for consecutive
patients with LARC and biopsy-proven rectal adenocarci-
noma who underwent neoadjuvant CRT followed by elective
radical surgery with TME with curative intent between
January 1, 2003 and December 31, 2011.
Admission criteria were patients with rectal cancers
located less than 12 cm tumor distance from anal verge and
clinical stage T2N +M0 or cT3/4 N0/+M0.
Exclusion criteria were patients with other diagnosed
neoplasia, short course RT, yp stage IV, R1/R2 surgery, and
death during 60 days postoperatively.
All patients receiving neoadjuvant CRT were operated
with an average of 8 weeks after the end of radiotherapy
and were included in this analysis. The patients receiving
short-course radiation were excluded since when immediate
surgery is carried out, no downstaging occurs.
Staging assessment included rigid proctoscopy, total
colonoscopy, chest, abdominal and pelvic CT scan, endo-
rectal ultrasound (ERUS), pelvic magnetic resonance image
(MRI) (since 2008), and carcinoembryonic antigen serum
levels.
Table 1: Mandard TRG system.
TRG1 No viable cancer cells, complete response
TRG2 Single cells or small groups of cancer cells
TRG3 Residual cancer outgrown by fibrosis
TGR4 Significant fibrosis outgrown by cancer
TRG5 No fibrosis with extensive residual cancer
The neoadjuvant CRT protocol included a total irradia-
tion of 50.4Gy in 28 fractions and 5-fluorouracil by infusion
pump.
Radical surgery consisted mainly of sphincter saving
rectal resection (SSRE) or abdominoperineal resection (APR)
with TME. In the operative procedure selection, we consid-
ered the distance of the lesion to the anus, the comorbidities
of the patient, and the condition of the anal sphincter.
Operated patients were subjected to adjuvant chemother-
apy protocol for 6 months performed preferably with 5-
fluorouracil (5-FU) or a combination of 5-FU and oxaliplat-
inum.
Standard pathologic tumor staging of the resected spec-
imen was performed in accordance with the guidelines of
the American Joint Committee on Cancer. Circumferential
resection margin (CRM) was scored as positive when cancer
cells were within 1mm of the margin. Evidence of ypCR was
defined as absence of viable adenocarcinoma in the surgical
specimen or the presence of lakes of mucus without tumor
cells. The histology of all surgical specimens was reviewed
and confirmed by an independent element and was classified
based on Mandard tumor regression grade system (Table 1).
We divided our patient population based on TRG Man-
dard into two groups: good responders defined as Man-
dard TRG1/TRG2 and bad responders defined as Mandard
TRG3/4/5. The two groups were used to evaluate outcome
results.
Disease recurrence was evaluated according to location:
locoregional (LR), systemic (DR), or mixed.
None of the patients were lost from followup.
All surviving patients were observed in our query in the
last three months.
2.1. Statistical Analysis. Survival time was defined as the
interval between the beginning of neoadjuvant therapy and
the date of the last observation.
Oncologic outcomes were evaluated for 5-year overall
survival (OS), 5-year disease-free survival (DFS), overall
recurrence (OR), local recurrence (LR), and distant recur-
rence (DR).
Survival curves were performed using the Kaplan-Meier
method and compared by log rank test.
Mandard groups (good/bad) were compared in relation
to age, sex, tumor distance from anal verge, clinical stage,
surgical procedure performed, and pathological stage (yp-
stage) using Student’s t-test and the𝑋2. For survival analysis,
the independent variables Mandard TRG, ypN-stage, the
ypT-stage, and tumor distance from anal verge were analyzed
using Cox’s proportional hazard (method forward stepwise).
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Table 2: Results—clinical parameters.
Variables
Sex
Male 87 (62.6%)
Female 52 (37.4%)
Age
Mean (range) 64.2 (32–82)
Tumor distance from anal verge
>6 cm 68 (48.9%)
≤6 cm 71 (51.1%)
Clinical stage
II 76 (54.7%)
III 63 (45.3%)
Neoadjuvant therapy
CRT 139
Surgical procedure
SSRR (sphincter saving rectal resection) 88 (63.3%)
APR (abdominoperineal resection) 46
Other (rectal resection without anastomose) 5
Perioperative complications
Morbidity 35 (25.1%)
Abdominal or pelvic abscess 11
Anastomose leak 2
Reoperation 5
Readmission 2
Was considered statistically significant 𝑝 < .05. IBM SPSS
Statistics version 20 was used.
3. Results
The database query returned 168 patients. We excluded 29
patients: 11 subjected to short course RT, 11 patients with free
radial margin ≤1mm (R1 surgery), 3 patients yp stage IV, and
four deaths in 60 days postoperatively.
3.1. Operative Procedure. The surgery performed in 139
patients was a sphincter saving rectal resection, with anas-
tomosis (with or without protective ileostomy) in 88 patients
(63.3%). Abdominal-perineal resection was performed in 46
patients, and five patients were subjected to proctectomywith
definitive stoma.
The morbidity of the series was 25.11% (Table 2).
3.2. Pathology. Stage distribution is shown in Table 3. The
average number of dissected lymph nodes in surgical spec-
imen was 8.2 (range 0–22).
Response to neoadjuvant therapy is characterized in
Table 3.
Classification of TRG according to Mandard system
allowed us to define two groups as previously mentioned:
TRG1 + 2 and TRG3 + 4 + 5.
We verified a good response to neoadjuvant CRT in 70
patients (ypCR in 25−17.9%) and a bad response in 69 patients
(49.6%).
Table 3: Results—pathological parameters and clinical long term
outcome.
Variables
Postoperative stage
0 25 (18%)
I 19 (13.7%)
II 53 (38.2%)
III 42 (30.2%)
TRGMandard 139
Good response (1 or 2) 70 (50.4%)
Bad response (3, 4, or 5) 69 (49.6%)
Overall recurrence disease 26 (18.7%)
Local 4 (2.9%)
Distant 20 (14.4%)
Local and distant 2 (1.4%)
Five years overall survival (os) 72.3% (se = 4.2%)
Five years disease survival (DFS) 72.1% (se = 4.1%)
The two groups of patients (good response Mandard
versus bad response Mandard) are statistically comparable
in respect to age (𝑝 = .12), sex (𝑝 = .52), clinical stage
(𝑝 = .11), and surgical procedures performed (𝑝 = .13) with
the exception of tumor distance from anal verge (𝑝 = .009),
ypN-stage (ypN0/ypN+) (𝑝 = .001), and ypT-stage (ypT0-
2/ypT3-4) (𝑝 < .001) (Table 4).
3.3. Disease Recurrence
3.3.1. Pelvic Recurrence. Four patients (2.9%) had isolated
pelvic recurrence. Considering only the group of patients
with a good response, pelvic recurrence appeared in 1 of 70
(1.4%) 45 months after surgery; TRG1 (Table 3).
3.3.2. Distant Recurrence. Distant recurrence without pelvic
recurrence appeared in 20 of 139 patients (14.4%). If we con-
sider only patients with a good response, distant recurrence
appeared in six of 70 (8.5%) patients (1/25 TRG1 and 5/45
TRG2). For patients who had a complete pathologic response,
distant recurrence emerged in one patient (brain metastasis
25 months after surgery).
3.3.3. Mixed Recurrence. Two patients (1.4%) had pelvic
and distant disease. Both were classified as bad responders
according to Mandard classification.
3.4. Survival. The mean followup was 56 months (range 6–
125). Five years overall survival (OS) and five years disease-
free (DFS) survival were 72.3% and 71.2%, respectively
(Table 3).
To the different subsets, survival at 5 years was matched
(Table 5).
The survival of patients who showed a good response on
Mandard TGRwas significantly higher than the patients with
poorer responses in 5-year overall survival (OS) and 5-year
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Table 4: Comparison between TRG and demographic and clinic variables.
Variables TRG1 + TRG2 TRG3 + TRG4 + TRG5 𝑝 value
Sex
Male 42 (60%) 45 (65.2%) .52
Female 28 (40%) 24 (34.7%)
Age
Mean (range) 63.1 66.1 .12
Tumor distance from anal verge
>6 cm 27 (38.5%) 41 (59.4%) .009
≤6 cm 43 (61.4%) 28 (40.5%)
Clinical stage
II 43 (61.4%) 33 (47.8%) .11
III 27 (38.5%) 36 (52.1%)
Surgical procedure
SSRR (sphincter saving rectal resection) 40 (57.1%) 48 (69.5%) .13
APR (abdominoperineal resection) + other (rectal resection without anastomose) 30 (42.8%) 21 (30.4%)
Pathological N-stage
ypN0 61 (87.1%) 36 (52.1%) .001
ypN+ 9 (12.8%) 33 (47.8%)
Pathological T-stage
ypT0 − 2 42 (60%) 7 (10.1%)
<.001
ypT3 + 4 28 (40%) 62 (89.9%)
Table 5: Results—TRG and clinical long term outcome. Univariable analysis followup: mean—56 months (range: 6–125).
CRT (𝑛 = 139)
Five years overall survival
Mandard good response (TRG1 + 2) 80.8% (se = 5.3%)
𝑝 = .013
a
Mandard bad response (TRG3+ 4 + 5) 63.4% (se = 6.4%)
Five years overall survival
ypCR (Mandard TRG1) 80.4% (se = 8.9%)
𝑝 = .77
a
Mandard partial response (TRG2) 81.0% (se = 6.7%)
Five years DFS
Mandard good response (TRG1 + 2) 81.7% (se = 5.1%)
𝑝 = .007
a
Mandard bad response (TRG3 + 4 + 5) 61.7% (se = 6.3%)
Five years DFS
ypCR (Mandard TRG1) 80.1% (se = 9.1%)
𝑝 = .71
a
Mandard partial response (TRG2) 82.8% (se = 6.1%)
Se: standard error.
aLog rank test.
disease-free survival (𝑝 = .013 and .007, resp.) as we can
observe in Table 4 and Figures 1 and 2.
In this series, no statistically significant survival differ-
ence was found when comparing patients with complete
(ypCR or Mandard TRG1) and partial pathological response
(Mandard TRG2) (OS 𝑝 = .77; DFS 𝑝 = .71) (Table 5).
Overall survival (OS) and DFS in patients with good
Mandard response were significantly better than those with
a bad response after we enter in the Cox model the following
variables: the ypN-stage (ypN0/ypN+), the ypT-stage, and the
distance from anal verge (Table 6).
4. Discussion
The aim of neoadjuvant CRT in LARC is cytoreduction
and downstaging of the tumor, but the tumor response to
neoadjuvant CRT is variable. Only when response is good,
sphincter preservation rate may increase and reduce the pos-
itive radial margin and the positive lymph node in resected
specimen (aspects related to rectal cancer prognosis) [17–
19, 34, 35]. Prognosis impact of tumor response assessment
by TRG is still controversial. Published data are inconclusive
[21, 36–42]. Despite uncertain clinical utility of TRG, recently
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Table 6: Survival in patients TRG (1 + 2) versus TRG (3 + 4 +
5) controlling ypN-stage (ypN0/ypN+), ypT-stage, and the distance
from anal verge multivariable analysis.
Hazard ratio (95% confidence interval) 𝑝 value
OS 0.46 (0.24–0.86) .016
DFS 0.43 (0.23–0.81) .007
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Figure 1: Five years overall survival comparison of the two groups
Mandard.
published 7th edition of TNM Staging Manual recommends
evaluation of TRG after chemoradiation of rectal cancer as a
routine procedure [43].
Tumor regression grades evaluate tumor response to
neoadjuvant treatment, mainly in CRT. There are several
tumor regression systems trying to quantify the response to
CRT and ultimately to have a prognostic value [20, 33, 38]. A
common, largely accepted, standardized, and validated TRG
system does not exist, so the published systems vary in the
definition of categories, interfering with studies results.
Mandard TRG was proved effective identifying sub-
groups with different responses. In our studies, we applied
Mandard system, which essentially counts the number of
residual tumor cells (Table 1). TRG1 identifies a complete
response (ypCR).
The association of tumor response and prognosis has
been previously reported. Previous reports have focused on
specific T or N downstaging and included in their analysis
pCR [44–46]. Other authors have emphasized the value of
tumor regression grade, which could more accurately reflect
tumor response at a cellular level [32, 33, 47]. In our series,
the application of the Mandard system allowed identification
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Figure 2: Five years disease-free survival comparison of the two
groups Mandard.
of two subgroups of patients with different impact in terms of
survival.
We had a complete pathological response in 25 patients
out of 139 patients (TRG1). A good response, defined as
Mandard 1 and 2 classifications, was present in 70 of 139
(50.4%) patients (Table 3). These percentages are consistent
with the available literature [35, 36].
In our series, we did not find a significant survival
difference comparing TRG1 with TRG2 (OS 𝑝 = .77; DFS
𝑝 = .71). When we consider TRG1 + TRG2 versus the
remaining TRG (3 + 4 + 5), we obtain significant different
survival values (𝑝 = .013). This aspect justified our patients
division in two different groups: good responders (TRG1+2)
and bad responders (TRG3 + 4 + 5). This type of Mandard
TRG division was already used by other authors [19, 36, 40].
While there are substantial data regarding the rela-
tionship between ypCR and improved oncologic outcomes,
the prognostic significance of near complete response to
neoadjuvant CRT has not been extensively evaluated. In
most studies, only the presence of a pathological complete
response is correlated to better long outcome and survival
improvement [48].
Beddy et al. [38] used Mandard TRG and observed
better DFS in the combined group of patients having either
complete response or near complete response (TRG0+TRG1)
compared with the remaining patients. Dhadda et al. [49]
applied Mandard system, and the results obtained suggested
improved DFS and OS after preoperative CRT in TRG2
versus TRG3 in the Cox regression analysis. Others series
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with different TGR system andmultivariate analyses failed to
demonstrate the prognostic value of TRG for DFS [21, 50].
In most studies, the pathologic T category and the nodal
status after neoadjuvant CRT still remain the most important
independent prognostic factors for DFS [21, 51].
The reason for these different results of the literature can
be related to several differences in number of patients of
the studies, followup interval, criteria of patients inclusion,
regimens of neoadjuvant CRT, time interval between CRT
and surgery, R1 definition, TRG system used, and different
adjuvant therapy protocols.
Comparing in our study Mandard TRG good response
versus Mandard TRG bad response, we find the following:
(i) Reduction rate of positive lymph nodes −uN+/ypN+
(64.7% versus 36.3%).
(ii) Lower disease recurrence (1.4% versus 7.2% concern-
ing LR; 8,5% versus 21.7% DR; 0% versus 2.8% mixed
recurrence).
(iii) Better survival (80.4% versus 63.4% concerning 5-
year OS, 𝑝 = .013; 81.7% versus 61.7% 5-year DFS,
𝑝 = .007).
Multivariate analyses confirmed the prognostic value of these
two TRG Mandard groups for OS and FDS: OS (𝑝 = .016);
DFS (𝑝 = .007).
A good response was associated with an improvement of
54% and 57% in overall survival, and disease-free survival
respectively.These results agreewith a recent publishedmeta-
analysis [31].
Our study is subject to biases and limitations: the series
is small, the histology of all surgical specimens was reviewed
retrospectively, and the study protocol did not provide extra
paraffin blocks from surgical specimen to confirm pCR
diagnoses. Another limitation of the present study is the
number of dissected lymph nodes: average 8.2 (0–22). The
advantages of our study were a single-institution database,
patientswith LARC treated in the sameway, and the histology
of all surgical specimens was reviewed and confirmed by an
independent and experimented pathologist.
According to data obtained, we identified a subset of
patients where the neoadjuvant CRT has the maximum effect
and better prognostic (subgroup with higher number of
patients than ypCR) and a subgroup of poorer prognosis
where other therapeutic regimenswill be needed to improved
survival.
5. Conclusion
Mandard good response (TGR1 + 2) was obtained in 50.4%
of our patients with LARC, treated with neoadjuvant CRT
and surgery. These patients were associated with lower
locoregional recurrence and improved survival compared
with Mandard bad response.
Mandard TRG assessment should be, in our opinion,
implemented in pathologic evaluation and prospectively
validated in further studies.
If Mandard TRG can predict long term outcomes, it
can help us to decide when a different adjuvant therapeutic
approach is indicated for the patients who undergo preoper-
ative chemoradiation and TME surgery with Mandard bad
response (TRG3 + 4 + 5).
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